[go: up one dir, main page]

DK3898668T5 - Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf - Google Patents

Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf Download PDF

Info

Publication number
DK3898668T5
DK3898668T5 DK19839558.4T DK19839558T DK3898668T5 DK 3898668 T5 DK3898668 T5 DK 3898668T5 DK 19839558 T DK19839558 T DK 19839558T DK 3898668 T5 DK3898668 T5 DK 3898668T5
Authority
DK
Denmark
Prior art keywords
antibodies
virus
neutralize hepatitis
neutralize
hepatitis
Prior art date
Application number
DK19839558.4T
Other languages
English (en)
Other versions
DK3898668T3 (da
Inventor
Davide Corti
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of DK3898668T3 publication Critical patent/DK3898668T3/da
Application granted granted Critical
Publication of DK3898668T5 publication Critical patent/DK3898668T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
DK19839558.4T 2018-12-19 2019-12-18 Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf DK3898668T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782274P 2018-12-19 2018-12-19
US201962860085P 2019-06-11 2019-06-11
PCT/US2019/067216 WO2020132091A2 (en) 2018-12-19 2019-12-18 Antibodies that neutralize hepatitis b virus and uses thereof

Publications (2)

Publication Number Publication Date
DK3898668T3 DK3898668T3 (da) 2023-11-13
DK3898668T5 true DK3898668T5 (da) 2024-08-05

Family

ID=69182688

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19839558.4T DK3898668T5 (da) 2018-12-19 2019-12-18 Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf

Country Status (24)

Country Link
US (2) US12304946B2 (da)
EP (2) EP3898668B1 (da)
JP (1) JP7498714B2 (da)
KR (1) KR102880569B1 (da)
CN (2) CN113544148B (da)
AU (1) AU2019403245B2 (da)
BR (1) BR112021012094A2 (da)
DK (1) DK3898668T5 (da)
ES (1) ES2961791T3 (da)
FI (1) FI3898668T3 (da)
HR (1) HRP20231440T1 (da)
HU (1) HUE063732T2 (da)
IL (2) IL284044B1 (da)
LT (1) LT3898668T (da)
MX (1) MX2021006756A (da)
MY (1) MY202685A (da)
PH (1) PH12021551458A1 (da)
PL (1) PL3898668T3 (da)
PT (1) PT3898668T (da)
SG (1) SG11202106483WA (da)
SI (1) SI3898668T1 (da)
TW (1) TWI892974B (da)
WO (1) WO2020132091A2 (da)
ZA (1) ZA202104213B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3898668T5 (da) 2018-12-19 2024-08-05 Humabs Biomed Sa Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf
MY206794A (en) 2018-12-20 2025-01-08 Humabs Biomed Sa Combination hbv therapy
EP4021578A1 (en) * 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
EP4171747A1 (en) 2020-06-24 2023-05-03 VIR Biotechnology, Inc. Engineered hepatitis b virus neutralizing antibodies and uses thereof
US20220235137A1 (en) 2020-10-14 2022-07-28 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4284428A1 (en) * 2021-01-26 2023-12-06 VIR Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
CN118139877A (zh) * 2021-10-18 2024-06-04 高丽大学校产学协力团 具有提高的pH依赖性FcRn结合力以及FcγRⅢa结合选择性的Fc变体
CN119546629A (zh) * 2022-05-19 2025-02-28 维尔生物科技公司 用于治疗丁型肝炎病毒（hdv）感染和相关疾病的组合物与方法
CN119403827A (zh) * 2022-05-19 2025-02-07 维尔生物科技公司 用于治疗乙型肝炎病毒(hbv)感染和hbv相关疾病的组合物和方法
AR129399A1 (es) 2022-05-23 2024-08-21 Vir Biotechnology Inc Anticuerpos diseñados neutralizantes del virus de la hepatitis b y usos de los mismos
WO2024148263A1 (en) * 2023-01-06 2024-07-11 Victorian Infectious Diseases Reference Laboratory Methods and compositions for antibody treatment of hepatitis b infection

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
CA2251904A1 (en) 1996-04-18 1997-10-23 Abbott Laboratories An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof
GB9608626D0 (en) 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
EP0948533A1 (en) 1996-12-30 1999-10-13 Innogenetics N.V. ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
CN1325517C (zh) * 1998-07-21 2007-07-11 展马博联合股份有限公司 抗丙型肝炎病毒抗体及其用途
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1848740A1 (en) 2005-01-14 2007-10-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, the Department of Health and Human Services, Monoclonal antibodies that bind or neutralize hepatitis b virus
AU2008254951A1 (en) 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
KR20090056537A (ko) 2007-11-30 2009-06-03 주식회사 녹십자 Ｂ형 간염 바이러스 중화능을 갖는 항체를 유효성분으로포함하는 ｂ형 간염 바이러스 감염의 예방 또는 치료용조성물
AU2009306010B2 (en) 2008-10-22 2015-12-24 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
EP2210903A1 (en) 2009-01-21 2010-07-28 Monoclonal Antibodies Therapeutics Anti-CD160 monoclonal antibodies and uses thereof
US8617554B2 (en) 2009-05-13 2013-12-31 Genzyme Corporation Anti-human CD52 immunoglobulins
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
MY178496A (en) 2012-07-10 2020-10-14 Green Cross Corp Antibody composition for prevention or treatment of mutant hepatitis b virus infection
KR102025679B1 (ko) 2012-08-30 2019-09-26 레플리코르 인코포레이티드 Ｂ형 간염 및 ｄ형 간염 감염증의 치료 방법
GB201216649D0 (en) 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
JP6445447B2 (ja) 2012-11-12 2018-12-26 ルプレヒト−カールス−ウニヴェルジテート ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ Ｈｂｖ及び／又はｈｄｖ感受性の細胞、細胞株及び非ヒト動物の開発
JP2016509582A (ja) 2012-12-19 2016-03-31 アンプリミューン， インコーポレイテッド 抗ヒトｂ７−ｈ４抗体およびその使用
US20140294812A1 (en) 2013-03-15 2014-10-02 Xencor, Inc. Fc variants that improve fcrn binding and/or increase antibody half-life
NZ722120A (en) 2014-01-16 2022-07-29 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
EP3191518B1 (en) 2014-09-12 2020-01-15 Genentech, Inc. Anti-b7-h4 antibodies and immunoconjugates
US10463732B2 (en) 2014-10-03 2019-11-05 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
PL3653221T3 (pl) 2015-02-19 2022-12-19 Compugen Ltd. Przeciwciała anty-pvrig i sposoby ich zastosowania
EP3261665A1 (en) * 2015-02-24 2018-01-03 The United States of America, as represented by The Secretary, Department of Health and Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
WO2017059878A1 (en) * 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
LT3390441T (lt) 2015-12-15 2021-11-10 Gilead Sciences, Inc. Žmogaus imunodeficito virusą neutralizuojantys antikūnai
AU2018266847A1 (en) 2017-05-10 2019-11-28 Albajuna Therapeutics, S.L. Fc-fusion protein derivatives with high dual HIV antiviral and immunomodulatory activity
CA3085472A1 (en) 2017-12-19 2019-06-27 The Rockefeller University Human igg fc domain variants with improved effector function
DK3898668T5 (da) 2018-12-19 2024-08-05 Humabs Biomed Sa Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf
MY206794A (en) * 2018-12-20 2025-01-08 Humabs Biomed Sa Combination hbv therapy
EP4021578A1 (en) 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection

Also Published As

Publication number Publication date
KR102880569B1 (ko) 2025-11-06
DK3898668T3 (da) 2023-11-13
BR112021012094A2 (pt) 2021-08-31
SG11202106483WA (en) 2021-07-29
SI3898668T1 (sl) 2024-02-29
PH12021551458A1 (en) 2022-05-02
US20250353900A1 (en) 2025-11-20
KR20210126558A (ko) 2021-10-20
AU2019403245A1 (en) 2021-07-22
PT3898668T (pt) 2023-12-06
CN118108836A (zh) 2024-05-31
HUE063732T2 (hu) 2024-01-28
CA3121004A1 (en) 2020-06-25
EP3898668B1 (en) 2023-08-30
EP4292659A2 (en) 2023-12-20
US12304946B2 (en) 2025-05-20
TW202039547A (zh) 2020-11-01
WO2020132091A3 (en) 2020-10-15
TWI892974B (zh) 2025-08-11
US20220127336A1 (en) 2022-04-28
EP4292659A3 (en) 2024-03-20
EP3898668A2 (en) 2021-10-27
CN113544148B (zh) 2024-04-05
WO2020132091A2 (en) 2020-06-25
FI3898668T3 (fi) 2023-11-28
HRP20231440T1 (hr) 2024-03-01
ES2961791T3 (es) 2024-03-13
JP2022514940A (ja) 2022-02-16
IL323376A (en) 2025-11-01
IL284044A (en) 2021-08-31
AU2019403245B2 (en) 2024-10-31
CN113544148A (zh) 2021-10-22
PL3898668T3 (pl) 2024-04-02
MX2021006756A (es) 2021-09-28
IL284044B1 (en) 2025-11-01
LT3898668T (lt) 2023-11-10
JP7498714B2 (ja) 2024-06-12
MY202685A (en) 2024-05-15
WO2020132091A9 (en) 2021-02-25
ZA202104213B (en) 2023-12-20

Similar Documents

Publication Publication Date Title
DK3898668T3 (da) Antistoffer der neutraliserer hepatitis b virus og anvendelser deraf
IL272183A (en) Anti-cd8 antibodies and uses thereof
IL280559A (en) Hepatitis b virus (hbv) dsrna agent compositions and methods of use thereof
DK3802608T3 (da) Anti-cd3-antistoffer og anvendelser deraf
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
EP3590942A4 (en) HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
EP3740224A4 (en) ANTI-LILRB ANTIBODIES AND THEIR USES
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
PT3468990T (pt) Anticorpos anti-c5 e utilizações dos mesmos
IL258326B (en) Antibodies that neutralize the hepatitis b virus in potency and their uses
DK3596125T3 (da) Anti-PAR2-antistoffer og anvendelser deraf
EP3904382A4 (en) ANTI-IL-23P19 ANTIBODIES AND ITS USES
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
IL281297A (en) Anti-npr1 antibodies and uses thereof
DK3402821T5 (da) Psma-bindende antistof og anvendelser deraf
IL281698A (en) Monomer and multimeric anti-hbv agents
IL271398A (en) Anti-l1-cam antibodies and uses thereof
DK3630143T3 (da) Onkolytisk virus og fremgangsmåde
IL283875A (en) Anti-il-27 antibodies and uses thereof
SG10201905229VA (en) Anti-Dengue Virus Antibodies and Applications Thereof
DK3448419T3 (da) Interferon-beta-antistoffer og anvendelser deraf
IL280281A (en) Anti-cd40 antibodies and uses thereof
IL279790A (en) Anti-l1cam antibodies and uses thereof
DK3580237T3 (da) Fgf21-mimetiske antistoffer og anvendelser deraf